Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Agios Pharmaceuticals Inc | AGIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
29.29 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 19.795 - 35.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 29.29 | USD |
Agios Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.65B | 56.19M | - | 26.82M | -352.09M | -6.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Agios Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 30.74 | 31.04 | 28.94 | 29.81 | 714,271 | -1.45 | -4.72% |
1 Month | 26.19 | 35.48 | 26.19 | 31.42 | 958,072 | 3.10 | 11.84% |
3 Months | 24.20 | 35.48 | 20.96 | 26.47 | 874,445 | 5.09 | 21.03% |
6 Months | 25.45 | 35.48 | 19.795 | 24.75 | 705,754 | 3.84 | 15.09% |
1 Year | 23.22 | 35.48 | 19.795 | 25.00 | 564,271 | 6.07 | 26.14% |
3 Years | 48.96 | 62.155 | 16.75 | 32.29 | 602,968 | -19.67 | -40.18% |
5 Years | 65.21 | 69.64 | 16.75 | 37.37 | 636,730 | -35.92 | -55.08% |
Agios Pharmaceuticals Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |